在非小细胞肺癌中,PD-L1表达与EGFR,ALK和ROS1驱动性瘤基因突变之间的关联
Dülger Onur1,2, Yaylım İlhan1, Öz Büge2
1Department of Molecular Medicine, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey.
Indian journal of pathology & microbiology
|June 21, 2024
概括
这项研究发现,PD-L1表达与非小细胞肺癌 (NSCLC) 的EGFR突变有负相关性. 在EGFR野生型患者中观察到更高的PD-L1表达,这表明PD-L1治疗益处可能会增加.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
背景情况:
- 驱动突变和免疫标记对NSCLC向治疗和免疫治疗至关重要.
- 了解基因突变和免疫标记之间的相互作用对于个性化治疗策略至关重要.
研究的目的:
- 为了研究PD-L1表达与NSCLC患者常见的驱动性瘤基因突变 (EGFR,ALK,ROS1) 之间的关联.
- 确定PD-L1表达与特定驱动突变相关的临床意义.
主要方法:
- 对501名NSCLC患者的分析.
- 通过免疫组织化学评估的PD-L1表达 (克隆22c3).
- 通过PCR检测出EGFR突变;通过FISH检测出ALK和ROS1重组.
主要成果:
- 在PD-L1表达和EGFR突变之间发现了显著的负相关性 (P=0.0002).
- 在EGFR野生型患者和非腺癌患者中,PD-L1表达更高.
- 在非吸烟者和腺癌中,ALK和ROS1重组以及EGFR突变更为普遍.
结论:
- 在NSCLC中,PD-L1表达与突变EGFR状态负相关.
- 在EGFR野生型患者中,PD-L1表达的更高表明PD-L1向治疗的潜力更大.
- PD-L1免疫组织化学可能会提高EGFR野生型NSCLC病例的临床预测.
更多相关视频
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
10.6K
09:32Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
14.6K
相关概念视频
02:39lncRNA - Long Non-coding RNAs
8.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
02:38Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K